431 results about "Nephropathy" patented technology

The invention relates to a nephrotic patient health management method and system based on a neural network prediction model, and the method comprises the steps: obtaining the multi-dimensional health data of a target nephrotic patient at each stage, constructing a time sequence feature matrix to extract the change trend of the whole course of disease, and dividing the course of disease into a disease alleviation stage and a disease deterioration stage; analyzing the health data of the two stages to obtain an improvement factor and a deterioration factor; outputting a renal function state prediction result by using a neural network prediction model fusing an attention mechanism and a knowledge graph, and generating an initial health management scheme by combining the result, a preset health management rule base and patient preferences; and optimizing the initial scheme based on the improvement factor, the deterioration factor and a reinforcement learning algorithm to obtain an optimized health management scheme. Complete-cycle closed-loop management of data acquisition, trend analysis, factor identification, prediction and early warning, scheme generation and dynamic optimization of nephropathy patients is realized, and the accuracy and individuation level of nephropathy health management are improved.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The embodiment of the invention discloses a model optimization method based on transfer learning. The method comprises the following steps: acquiring to-be-migrated learning data, wherein the to-be-migrated learning data comprises source domain data associated with pathological characteristics of kidney diseases; semantic alignment processing is carried out on the source domain data and target domain data, the target domain data is kidney disease pathology data, and a semantic alignment result is obtained; determining a feature distribution result corresponding to the target domain data, and determining a migration weight corresponding to the source domain data based on the feature distribution result and the semantic alignment result; and optimizing the target domain model based on the migration weight, the source domain data and the target domain data to obtain an optimized target domain model. According to the embodiment of the invention, the accuracy and robustness of the target domain model in a kidney disease pathological diagnosis task and the generalization ability of different data distributions can be remarkably improved.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention relates to thiophenyl derivatives and their use in the treatment and prophylaxis of diseases alleviated by APOL1 inhibition, such as an APOL1 mediated kidney disease, and to compositions containing said derivatives and processes for their preparation.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing into a kidney disease by administering an angiopoietin-like 3 (ANGPTL3) inhibitor and a solute carrier family 5 member 2 (SLC5A2) inhibitor, and methods of identifying a subject having an increased risk of developing into a kidney disease.

The invention relates to the technical field of gene engineering, in particular to a method for constructing a pou3f3 mutant model, the pou3f3 mutant model and application. The method comprises the following steps: designing an sgRNA target nucleotide sequence of a targeted pou3f3 gene, shearing the pou3f3 gene in an animal model through a CRISPR / Cas9 gene editing technology so as to realize pou3f3 gene mutation, and finally carrying out passage screening to obtain a double homozygous mutant of pou3f3a mutation and pou3f3b mutation, a pou3f3a homozygous mutant or a pou3f3b homozygous mutant model. According to the method, synchronous knockout of the two homologous genes pou3f3a and pou3f3b can be effectively realized, a reliable experimental model is provided for researching gene functions and related diseases, and the model can also be used for researching hereditary kidney diseases.

The invention relates to the field of medical treatment, in particular to application, a model and a method of a protein fragment of urine regulatory protein in preparation of a kidney disease early detection product, and the amino acid sequence of the protein fragment of the urine regulatory protein is any shown in SEQ ID NO.1-8. The model constructed according to the protein fragment of the urine regulatory protein can be used as a non-invasive tool for early detection and monitoring of kidney diseases, and by analyzing the unique mode of the protein fragment existing in a urine sample, the model which indicates renal insufficiency, renal function and renal function can be identified before the traditional clinical biomarker is abnormal. Therefore, intervention can be carried out earlier.

The invention discloses a preparation method of a myeloid cell triggered receptor 2 protein polyclonal antibody and application of the polyclonal antibody in inhibition of renal fibrosis, and belongs to the technical field of medical molecular biology. The myeloid cell triggered receptor 2 protein is expressed by macrophages, and verification in the mechanism aspect is carried out on the protein; meanwhile, the polyclonal antibody is synthesized according to the polypeptide of the protein, then the effect of the antibody on treating the renal fibrosis is verified again, and a more targeted and personalized method is provided for diagnosis, treatment and management of the renal fibrosis and related kidney diseases.

The invention provides a construction method and system of a heart failure risk prediction model based on medical big data and a machine learning algorithm, and a medium, and the construction method comprises the steps: screening a medical information database, and obtaining a kidney patient group information data set; preprocessing the data set, dividing a training set, a verification set and a plurality of candidate prediction factors related to the heart failure risk, performing importance sorting, and training through a machine learning algorithm according to an importance sorting result and the training set to obtain a plurality of candidate heart failure risk prediction models; and evaluating and comparing the candidate models according to the verification set, and finally obtaining a heart failure risk prediction model. The heart failure risk prediction model specially designed for the chronic kidney patient group is constructed based on the medical big data and the machine learning algorithm, the heart failure risk prediction accuracy for the kidney patient group can be effectively improved, and the method can be widely applied to the technical field of medical information prediction.

The invention relates to the technical field of medical care informatics, in particular to a nephropathy medication interaction risk screening system which comprises a data acquisition unit, an SOC chip processing and analysis unit, a risk early warning unit and a man-machine interaction and communication unit. Through multi-source data access, dynamic weight scheduling and Kalman filtering fusion correction, accurate and on-demand acquisition of nephropathy core indexes is realized, and real-time intelligent discrimination of personalized medication risks is realized by relying on knowledge base support, adaptive path adjustment and a safe atomization updating mechanism, so that the risk of the nephropathy is accurately determined. Therefore, the problems that traditional system data acquisition lacks specialized pertinence, risk assessment personalization is insufficient, and model updating is lagged are effectively solved, and the accuracy and timeliness of nephropathy medication interaction risk screening are remarkably improved.

The invention discloses a remote home dialysis data management cloud platform for nephropathy and a data analysis method, and relates to the technical field of home medical treatment, the remote home dialysis data management cloud platform comprises a data acquisition module, a data cloud end and an interaction terminal; the data acquisition module comprises a dialysis process data acquisition unit used for acquiring real-time dialysis data in the household dialysis process of a user; the home behavior data acquisition unit is used for acquiring user home behavior data; the data cloud comprises a cloud data storage module used for storing real-time dialysis data and user home behavior data in the user home dialysis process collected by a data collection module; the cloud data analysis module is used for analyzing whether the home dialysis treatment of the user is abnormal or not; and the virtual diagnosis and treatment module is used for constructing a virtual diagnosis and treatment room. The system has the advantages that an intelligent management mode is adopted, so that the treatment effect and the management efficiency of home dialysis are remarkably improved, and a safer and more convenient medical service solution is provided for patients with chronic kidney diseases.

The invention relates to the technical field of preparation of organoids, and discloses a method for regulating and controlling human induced pluripotent stem cells to differentiate into kidney organoids, which comprises the following steps: resuspending a cell cluster formed by human induced pluripotent stem cells by using a basic differentiation culture solution containing a GSK-3beta inhibitor, inoculating the cell cluster into an ultralow adsorption cell culture plate, and starting to culture, marking the time as the 0th hour of differentiation; and after culturing for 70-76 hours, replacing the basic differentiation culture solution containing the GSK-3beta inhibitor with a basic differentiation culture solution containing a Knockout TM serum substitute (KSR), and continuing to carry out differentiation culture. By adopting the method disclosed by the invention, the human induced pluripotent stem cells can be efficiently, quickly, simply, conveniently and stably subjected to directional induced differentiation into kidney organs containing podocytes, renal tubules and other structures, and the time for constructing a kidney in-vitro model can be shortened, so that the research on kidney diseases, kidney development and the like can be greatly assisted; and a powerful platform is provided for kidney toxicity assessment.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat Cys-C protein and application. The monoclonal antibody combination provided by the invention comprises monoclonal antibodies 4D5 and 3F3, and amino acid sequences of complementary determining regions (CDR) of variable regions of a heavy chain and a light chain of the monoclonal antibodies 4D5 and 3F3 are respectively shown as SEQ ID NO.1 to SEQ ID NO.12. The antibody combination has high specificity and sensitivity, and can effectively recognize cat Cys-C recombinant protein and natural cat Cys-C protein. According to the double-antibody sandwich ELISA detection method constructed based on the antibody combination, positive signals can still be generated under the low concentration of 1ng / mL, no obvious cross reaction exists, and the detection accuracy is remarkably improved. The antibody combination can be used for preparing a detection kit, a test strip, an antibody chip and other tools, and is suitable for cat kidney function evaluation and early auxiliary diagnosis of kidney diseases.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to penetrate a skin of a patient and generate a sensor current indicative of analyte levels of the patient, and a sensor electronics module coupled to the continuous analyte sensor. The sensor electronics module comprises an analog to digital converter configured to receive the sensor current and convert the sensor current generated by the continuous analyte sensor into digital signals, a processor configured to convert the digital signals to a set of analyte measurements indicative of the analyte levels of the patient, and a Bluetooth antenna configured to transmit the set of analyte measurements wirelessly to a wireless communications device using Bluetooth or BLE communications protocols.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention relates to the technical field of image recognition, and discloses an image feature recognition method and system applied to the early stage of kidney diseases. According to the method, the features in the original ultrasonic image are extracted in parallel, and the micro texture change and the macroscopic form information shown in the abnormal area can be captured respectively, so that the limitation of a traditional single-scale feature extraction method in coping with diffusive and weak-saliency image features is overcome; the local texture feature map and the global structure feature map are analyzed, quantization and positioning of weak texture changes are achieved, priori knowledge is converted into objective indexes, pixel-level fusion is carried out on a texture abnormal map and a region importance weight map, and through the knowledge-guided and data-driven deep fusion method, the deep fusion of the texture abnormal map and the region importance weight map is achieved. It is ensured that the finally recognized abnormal area is not only a statistical outlier but also conforms to importance distribution of an image structure, and high-precision automatic recognition of weak and diffuse features in the kidney medical image is facilitated.

The invention discloses a chronic kidney disease pathological image recognition enhancement system which integrates a data collection module, a kidney disease pathological modeling module, a pathological evolution enhancement module and an image recognition enhancement module, belongs to the technical field of pathological image enhancement, and particularly relates to the chronic kidney disease pathological image recognition enhancement system. Through multi-modal data acquisition, adaptive illumination compensation and image registration reconstruction, renal unit three-dimensional structure modeling is realized; a three-dimensional space-time diagram convolutional network is combined, space structure, time dynamic and clinical features are fused, and the stability and interpretability of pathology evolution prediction are improved; finally, based on the pre-training recognition model and the visual thermodynamic diagram, the precision and clinical availability of pathological image recognition are enhanced, and the intelligent and collaborative level of pathological recognition is effectively improved.

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.

The invention discloses a potential nephropathy prediction electronic nose system and method based on machine learning, and belongs to the technical field of medical detection. According to the system, ammonia concentration and temperature and humidity parameters in exhaled air of a human body are collected through a multi-mode sensor module, baseline calibration, flow velocity compensation and noise filtering are carried out in combination with a data preprocessing module, and a standardized characteristic matrix is generated. The machine learning prediction model adopts a Bayesian deep learning or integrated learning algorithm, inputs an ammonia concentration peak value, an integral area and temperature and humidity parameters, outputs a nephropathy risk probability and stage prediction, and quantifies key influence factors through an SHAP value (for example, a high-risk alarm is triggered when an ammonia concentration contribution degree is greater than or equal to 60%). The system is equipped with a real-time GUI interaction interface, dynamically displays a risk thermodynamic diagram and multi-dimensional data overlay analysis, and supports clinicians to feed back and correct. And the data iteration module realizes continuous optimization of the model through an encrypted cloud storage and incremental learning framework (Online SGD). A heterogeneous sensor array (such as a Fe2Mo3O8 / MoO2 (at) MoS2 composite material) and a dynamic temperature and humidity compensation technology are adopted, so that the detection stability is remarkably improved, and the clinical misdiagnosis rate is reduced. The system can be integrated in a portable device or a hospital system, is suitable for community screening, emergency triage and remote medical scenes, and has the advantages of noninvasive, high-precision and cross-mechanism collaborative diagnosis.

Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

The invention relates to proteins for use in the prevention, treatment or amelioration of kidney diseases or kidney damage, more particularly where the protein is a follistatin-fusion protein.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present disclosure provides a method and an apparatus for predicting a progression trajectory from acute kidney injury (AKI) to a kidney disease. The method includes the following steps: receiving a first set of features of a particular acute kidney injury (AKI) patient; selecting a second set of features from the first set of features using a preset algorithm; and predicting, using a first machine-learning model, a progression trajectory of a kidney disease of the particular AKI patient based on the second set of features.

Provided herein are compounds that are useful in treating cancer, metabolic disease, cardiovascular disease, and kidney disease.